An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.

Inclusion Criteria

• •Males and female subjects between 18-65 years of age (only in Germany: Males and females between 12 - 65 years of age in order to follow national medical society guidelines)
• •Female subjects must be neither pregnant nor breast-feeding and must lack child-bearing potential as defined by either: a) Post-menopausal or surgically sterile, or b) Using a highly effective method of contraception for the duration of the study. This is defined as a method that results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly, and includes for instance implants, injectables, combined oral contraceptives, intra-uterine device (IUD), sexual abstinence or vasectomised partner
• •Subjects diagnosed with Relapsing MS according to the revised McDonald Criteria (2005)
• •MS-treatment naïve subjects or subjects treated with Rebif multi-dose injected by RebiSmart for no longer than 6 weeks prior to Baseline visit
• •Subjects that are able to self-inject with RebiSmart (in the opinion of the physician)
• •Subjects with Expanded Disability Status Scale (EDSS) score \< 6 (inclusive) at Baseline
• •Signed informed consent (in countries where subject signature is not mandatory: subject must be given the patient information)